-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Non-alcoholic fatty liver disease (NAFLD) is the fastest growing chronic liver disease, epidemiological data show that the current global prevalence of NAFLD is 25%, and now China is in the rapid development of NAFLD, the national prevalence rate as high as 29.2%.
, NAFLD increases the risk of cirrhosis and hepatocellular carcinoma.
in the U.S., direct medical costs are about $103 billion ($1,613 per patient) a year, and in Europe they cost 35 billion euros (from 354 euros to 1,163 euros per patient).
NAFLD is closely related to metabolic syndrome and related conditions, including obesity, type 2 diabetes, dyslipidemia, hypertension and hyperureticemia.
previous studies have shown an independent link between high uric acidemia and the severity of liver damage in NAFLD.
therefore, the purpose of this study is to explore whether obesity can alter the relationship between serum uric acid and the severity of liver damage in NAFLD, as well as the possible interaction between high uric acidemia and obesity.
researchers conducted cross-sectional studies of a total of 557 ultrasound-diagnosed NAFLDs.
the degree of liver fatty degeneration and liver fibrosis with transient elastic imaging.
high uric acidemia is defined as serum uric acid in men, 420 smol/L in women, and obesity as body mass index ≥25 kg/m2.
the OR values of adjusted high uric acidemia and obesity through multiple logistic regression analysis, and used the addition model to study possible interactions.
multi-regression analysis showed that high uric acidemia was associated with severe liver fat degeneration (1.74 (1.09-2.79)) and ALT elevation (2.17 (1.38-3.41)) and not with late fibrosis (1.61 (0.91-2.85).
same time, the researchers found that in obese NAFLD alone, high uric acidemia was associated with a higher risk of severe liver fat degeneration (2.02 (1.14-3.57)) and elevated ALT (2.27 (1.37-3.76)), as was not the case in non-obese subjects.
same time, people with high uric acidemia are more likely to develop fibrosis in obese people (2.17 (1.13-4.18) than non-obese people (0.60 (0.14-2.70) are not.
addition, there is an interaction between high uric acidemia and obesity in the likelihood of severe liver fat degeneration (AP: 0.39 (0.01-0.77)) and late fibrosis.
study confirms that high uric acidemia and obesity have significant synergies between liver fat degeneration and fibrosis.
, treatment for uric acid may be needed in obese NAFLD.